Directorate Change
17 September 2012
Adrian Hennah appointed CFO at RB
Reckitt Benckiser (RB) announces that Liz Doherty, Chief Financial Officer
(CFO), is stepping down from the role. Adrian Hennah, currently CFO Smith &
Nephew, is appointed as new CFO for RB.
Commenting, Rakesh Kapoor, CEO, said
"I am pleased to welcome Adrian Hennah as CFO. His global experience,
especially in the health care industry, will be very valuable as we execute our
strategy of extending our health and hygiene Powerbrands internationally, with
a particular focus on emerging markets."
"I want to thank Liz for her excellent support over the past two years. She has
strengthened our finance function around the world, and has been instrumental
in helping to ensure a smooth CEO transition for the business. However, Liz and
I have agreed that RB's and her way of working are not as well matched as
either of us would like, and now is the right time for her to move to a new
opportunity."
Liz Doherty will stay with the business until March 2013 and Adrian Hennah will
join at end December 2012. This overlap will help ensure a smooth transition
during the year-end period.
Ends
Under listing rule Listing Rule 9.6.13 note:
1. Mr Hennah is also a non-executive director of Reed Elsevier plc
2. There are no further details required to be disclosed pursuant to Listing
Rule 9.6.13 in connection with Mr Hennah's appointment.
Notes to editors:
Biography of Adrian Hennah
Adrian is chief financial officer at Smith & Nephew plc, the international
medical devices company listed on the UK stock exchange (FTSE50) and with a
market capitalisation of approximately $10bn. He has held this role since 2006
and has been instrumental in helping the business to focus on improving
efficiency in maturing markets and growth in emerging markets, especially
China.
For the four years prior to this (2002-2006), Adrian was chief financial
officer of Invensys, the international engineering company with a £2bn turnover
and about 30,000 staff around the world.
Adrian spent most of his earlier career (1984-2002) at GlaxoSmithKline plc
(GSK), one of the world's largest pharmaceutical companies with a market
capitalisation of over £71bn. Most recently he held the role of SVP finance and
operations GSK research and development. He also held roles including CFO of
GlaxoWellcome USA and finance director Glaxo UK, in addition to general
management.
Adrian worked at PWC (then Price Waterhouse) both in audit and consultancy from
1980-1984, and from 1978-1980 worked in Stadtsparkasse Koeln, the German
regional bank.
Adrian is a non-executive director of Reed Elsevier.
He was educated at London Business School (Sloan Fellowship Programme), FCA,
and has an MA in Law & Economics from Cambridge University.
Adrian lives in Newbury, with his partner and four children.
About Reckitt Benckiser
Reckitt Benckiser (RB) is a global consumer goods leader in health, hygiene and
home.
With a purpose of delivering innovative solutions for healthier lives and
happier homes, RB is in the top 25 of companies listed on the London Stock
Exchange. Since 2000 net revenues have doubled and the market cap has
quadrupled. Today it is the global No 1 or No 2 in the majority of its
fast-growing categories, driven by an exceptional rate of innovation. It's
health, hygiene and home portfolio is led by 19 global powerbrands including
Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Lysol, Dettol, Clearasil,
Veet, Harpic, Bang, Mortein, Finish, Vanish, Woolite, Calgon, Airwick, and
French's, and they account for 70% of net revenue.
RB people are at the heart of the company's success. They have an intense drive
for action and a desire to outperform wherever they focus, including in CSR
where the company is reducing its Carbon footprint by 20% by 2020 and has a
global partnership with Save the Children.
The company has operations in over 60 countries, with headquarters in the UK,
Singapore, Dubai and Amsterdam, and sales in almost 200 countries. The company
employs about 38,000 people worldwide.
For more information visit www.rb.com
=======
For further information:
Investor enquiries, contact:
Richard Joyce, RB +44(0)1753 217800
Press enquiries, contact:
Andraea Dawson-Shepherd, RB +44 (0)1753 446 447
David Litterick, Brunswick +44 (0) 207 7396 7455